相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD)
Wright W. Nichols et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)
Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing Enterobacterales?: a Systematic Review and Meta-analysis
Burcu Isler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes
Pauline A. Lang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Class D β-lactamases
Eun-Jeong Yoon et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Evaluation of the post-antibiotic effect in vivo for the combination of a β-lactam antibiotic and a β-lactamase inhibitor: ceftazidime-avibactam in neutropenic mouse thigh and lung infections
Johanna Berkhout et al.
JOURNAL OF CHEMOTHERAPY (2021)
Multidrug-resistant Klebsiella pneumoniae: mechanisms of resistance including updated data for novel β-lactam-β-lactamase inhibitor combinations
Irene Galani et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)
Molecular Basis of AmpC β-Lactamase Induction by Avibactam in Pseudomonas aeruginosa: PBP Occupancy, Live Cell Binding Dynamics and Impact on Resistant Clinical Isolates Harboring PDC-X Variants
Silvia Lopez-Arguello et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Ceftazidime-avibactam: are we safe from class A carbapenemase producers' infections?
Natalia Kehl Moreira et al.
FOLIA MICROBIOLOGICA (2021)
Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies
Stefano Di Bella et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
George L. Daikos et al.
ANTIBIOTICS-BASEL (2021)
Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review
Alex Soriano et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Biochemical Activity of Vaborbactam
Ruslan Tsivkovski et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
A Standard Numbering Scheme for Class C β-Lactamases
Andrew R. Mack et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Ceftazidime-Avibactam Resistance Associated with Increased blaKPC-3 Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 Klebsiella pneumoniae
Marco Coppi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Mechanism of proton transfer in class A β-lactamase catalysis and inhibition by avibactam
Orville A. Pemberton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion
Akito Kawai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Resistance to ceftazidime-avibactam and underlying mechanisms
Yuhang Wang et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor
Dor Russ et al.
NATURE COMMUNICATIONS (2020)
In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula
Agnes Sonnevend et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations The Price of Progress
Krisztina M. Papp-Wallace et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2020)
A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring blaKPC-14 Isolated in New York City
Siqiang Niu et al.
MSPHERE (2020)
New beta-Lactam-beta-Lactamase Inhibitor Combinations
Dafna Yahav et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia
Shampa Das et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam
I. Galani et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Molecular Insights on the Release of Avibactam from the Acyl-Enzyme Complex
Ignacio Lizana et al.
BIOPHYSICAL JOURNAL (2019)
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa
Jose-Manuel Ortiz de la Rosa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity
Saoussen Oueslati et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points
Aatoni Torres et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals
Mariana Castanheira et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Molecular Basis of Class A β-Lactamase Inhibition by Relebactam
Catherine L. Tooke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors
Ryan L. Crass et al.
PHARMACOTHERAPY (2019)
Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review
Felipe Francisco Tuon et al.
INFECTION (2018)
Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Combination of Amino Acid Substitutions Leading to CTX-M-15-Mediated Resistance to the Ceftazidime-Avibactam Combination
Fabrice Compain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae
Dhruvitkumar S. Sutaria et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis
Neta Sternbach et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Past and Present Perspectives on β-Lactamases
Karen Bush
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015
Krystyna M. Kazmierczak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Evolution of Plasmid-Mediated Antibiotic Resistance in the Clinical Context
Alvaro San Millan
TRENDS IN MICROBIOLOGY (2018)
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations
Sarah M. McLeod et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
AmpC β-lactamase induction by avibactam and relebactam
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 β-Lactamase
Fabrice Compain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Exploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 β-Lactamase
Melina Ruggiero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases
Ghady Haidar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M15 Harboring the Substitution N132G in the Conserved SDN Motif
Clement Ourghanlian et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
Johanna Berkhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria
Abdelhamid Asli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam
Jean-Marie Pages et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
Krystyna M. Kazmierczak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
A Structure-Based Classification of Class A beta-Lactamases, a Broadly Diverse Family of Enzymes
Alain Philippon et al.
CLINICAL MICROBIOLOGY REVIEWS (2016)
In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms
Gabriel Torrens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition
Sushmita D. Lahiri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)
Boudewijn L. M. de Jonge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Interaction of Avibactam with Class B Metallo-β-Lactamases
Martine I. Abboud et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms
Roopali Sharma et al.
CLINICAL THERAPEUTICS (2016)
Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain
Tommaso Giani et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2016)
Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections
Bradley J. Gardiner et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2016)
The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam
David Yuxin Wang et al.
FUTURE MEDICINAL CHEMISTRY (2016)
Klebsiella pneumoniae blaKPC-3 nosocomial epidemic: Bayesian and evolutionary analysis
Silvia Angeletti et al.
INFECTION GENETICS AND EVOLUTION (2016)
New β-Lactamase Inhibitors in the Clinic
Krisztina M. Papp-Wallace et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2016)
Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations
Sushmita D. Lahiri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections
Marco Falcone et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
The postantibiotic effect and post--lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria
C. M. Pillar et al.
LETTERS IN APPLIED MICROBIOLOGY (2016)
What does research reproducibility mean?
Steven N. Goodman et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
Kellie J. Goodlet et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Avibactam and Inhibitor-Resistant SHV β-Lactamases
Marisa L. Winkler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Variants of β-Lactamase KPC-2 That Are Resistant to Inhibition by Avibactam
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from US Hospitals (2011 to 2013) and Characterization of β-Lactamase-Producing Strains
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of Ceftazidime-Avibactam against Fluoroquinolone-Resistant Enterobacteriaceae and Pseudomonas aeruginosa
C. Pitart et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases
Krisztina M. Papp-Wallace et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2015)
Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC
Sushmita D. Lahiri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop
Marisa L. Winkler et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients
Hussein Chalhoub et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'
Akihiro Morinaka et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations
Ayumi Yoshizumi et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2015)
A β-lactamase inhibitor revival provides new hope for old antibiotics
Ken Garber
NATURE REVIEWS DRUG DISCOVERY (2015)
The -Lactams Strike Back: Ceftazidime-Avibactam
Evan J. Zasowski et al.
PHARMACOTHERAPY (2015)
Natural Variants of the KPC-2 Carbapenemase have Evolved Increased Catalytic Efficiency for Ceftazidime Hydrolysis at the Cost of Enzyme Stability
Shrenik C. Mehta et al.
PLOS PATHOGENS (2015)
Mechanisms of antimicrobial resistance in Gram-negative bacilli
Etienne Ruppe et al.
ANNALS OF INTENSIVE CARE (2015)
Molecular Mechanism of Avibactam-Mediated β-Lactamase Inhibition
Dustin T. King et al.
ACS INFECTIOUS DISEASES (2015)
Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48
Sushmita D. Lahiri et al.
ACS CHEMICAL BIOLOGY (2015)
In Vitro Susceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations
Henry Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Activity of Ceftazidime-Avibactam Combination in In Vitro Checkerboard Assays
Johanna Berkhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa
Marisa L. Winkler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
β-Lactamase inhibition by avibactam in Mycobacterium abscessus
Vincent Dubee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study
Nikhil P. Krishnan et al.
PLOS ONE (2015)
In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam against 372 Gram-Negative Bacilli Collected in 2011 and 2012 from 11 Teaching Hospitals in China
Xiaojuan Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
Sarah M. Drawz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine US Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-Lactamases
Premavathy Levasseur et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Reclaiming the Efficacy of β-Lactam-β-Lactamase Inhibitor Combinations: Avibactam Restores the Susceptibility of CMY-2-Producing Escherichia coli to Ceftazidime
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance
S. D. Lahiri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
Tiffany R. Keepers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
Ken Coleman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Inactivation of TEM-1 by Avibactam (NXL-104): Insights from Quantum Mechanics/Molecular Mechanics Metadynamics Simulations
Jacopo Sgrignani et al.
BIOCHEMISTRY (2014)
Dissemination of carbapenemase-producing Enterobacteriaceae in France, 2012
Laurent Dortet et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme
Sushmita D. Lahiri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Avibactam activity against extended-spectrum AmpC β-lactamases
Nerea Porres-Osante et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries
Mariana Castanheira et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Class D β-Lactamases: A Reappraisal after Five Decades
David A. Leonard et al.
ACCOUNTS OF CHEMICAL RESEARCH (2013)
Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases
Sushmita D. Lahiri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Investigational Antimicrobial Agents of 2013
Michael J. Pucci et al.
CLINICAL MICROBIOLOGY REVIEWS (2013)
Ceftazidime-Avibactam: a Novel Cephalosporin/beta-lactamase Inhibitor Combination
George G. Zhanel et al.
DRUGS (2013)
Intercontinental spread of OXA-48 beta-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011
A Potron et al.
Eurosurveillance (2013)
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
David E. Ehmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study
Mikhail V. Edelstein et al.
LANCET INFECTIOUS DISEASES (2013)
Variations within Class-A β-Lactamase Physiochemical Properties Reflect Evolutionary and Environmental Patterns, but not Antibiotic Specificity
Deeptak Verma et al.
PLOS COMPUTATIONAL BIOLOGY (2013)
Carbapenemases: Partners in crime
Karen Bush
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2013)
The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β -lactamase in Enterobacter cloacae
Christine Miossec et al.
Infection and Drug Resistance (2013)
NXL104 Irreversibly Inhibits the β-Lactamase from Mycobacterium tuberculosis
Hua Xu et al.
BIOCHEMISTRY (2012)
In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
Z. Aktas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
OXA-48-like carbapenemases: the phantom menace
Laurent Poirel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor
David E. Ehmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Epidemiological Expansion, Structural Studies, and Clinical Challenges of New beta-Lactamases from Gram-Negative Bacteria
Karen Bush et al.
ANNUAL REVIEW OF MICROBIOLOGY, VOL 65 (2011)
Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Emergence of Ertapenem Resistance in an Escherichia coli Clinical Isolate Producing Extended-Spectrum β-Lactamase AmpC
Helene Guillon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)
A. Walkty et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
P. R. S. Lagace-Wiens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
OXA-163, an OXA-48-Related Class D β-Lactamase with Extended Activity Toward Expanded-Spectrum Cephalosporins
Laurent Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Ken Coleman
CURRENT OPINION IN MICROBIOLOGY (2011)
Global Spread of Carbapenemase-producing Enterobacteriaceae
Patrice Nordmann et al.
EMERGING INFECTIOUS DISEASES (2011)
Diversity, Epidemiology, and Genetics of Class D beta-Lactamases
Laurent Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Updated Functional Classification of beta-Lactamases
Karen Bush et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Differential Selection of Single-Step AmpC or Efflux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or Ceftobiprole
Anne Marie Queenan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase Inhibitor
Therese Stachyra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Genetic Determinants Involved in the Susceptibility of Pseudomonas aeruginosa to β-Lactam Antibiotics
Carolina Alvarez-Ortega et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study
Karthikeyan K. Kumarasamy et al.
LANCET INFECTIOUS DISEASES (2010)
Complete Genome Sequence of the Multiresistant Taxonomic Outlier Pseudomonas aeruginosa PA7
Paul H. Roy et al.
PLOS ONE (2010)
Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa
Jose-Manuel Rodriguez-Martinez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In Vitro Activity of NXL104 in Combination with β-Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases
Andrea Endimiani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
Therese Stachyra et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Patrice Nordmann et al.
LANCET INFECTIOUS DISEASES (2009)
NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Carbapenemases: molecular diversity and clinical consequences
Laurent Poirel et al.
FUTURE MICROBIOLOGY (2007)
Extension of the hydrolysis spectrum of AmpC β-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix
Hedi Mammeri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
OXA-1 is OXA-30 is OXA-1
David A. Boyd et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Naturally occurring extended-spectrum cephalosporinases in Escherichia coli
Hedi Mammeri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
OXA-type carbapenemases
J Walther-Rasmussen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Bacterial cell wall synthesis: New insights from localization studies
DJ Scheffers et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2005)
Extended-spectrum β-lactamases:: a clinical update
DL Paterson et al.
CLINICAL MICROBIOLOGY REVIEWS (2005)
Characterization of poxB, a chromosomal-encoded Pseudomonas aeruginosa oxacillinase
KF Kong et al.
GENE (2005)
Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase:: Defining a unique family of class C enzymes
KM Hujer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Is it necessary to change the classification of β-lactamases?
JM Frère et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Post-antibiotic and post-β-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum β-lactamase-producing Gram-negative bacteria
JP Lavigne et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor
A Bonnefoy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae
GA Jacoby et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa
D Girlich et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat
PA Bradford
CLINICAL MICROBIOLOGY REVIEWS (2001)
GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem
L Poirel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa
D Aubert et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Mutagenesis of amino acid residues in the SHV-1 β-lactamase:: the premier role of Gly238Ser in penicillin and cephalosporin resistance
AM Hujer et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY (2001)
分享论文
